Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 237 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Elderly Immune System Clear all
Completed Phase 2 Interventional Results available

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy

NCT01626352
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Bendamustine, Ofatumumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
70 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Fort Myers, Florida • Pensacola, Florida • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Jun 26, 2026, 10:13 AM EDT
Enrolling by invitation Not applicable Interventional

Promoting Aging and Thriving With HIV

NCT07192419
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Geriatric, Geriatric Assessment, HIV, HIV - Human Immunodeficiency Virus
Interventions
Promoting Aging and Thriving with HIV (PATH)-Implementation of a Tailored Geriatric Assessment and Management Strategy for HIV Care Settings
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 3 Interventional Results available

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

NCT02483975
View directory record Official record
Conditions
Asthma
Interventions
FF, Placebo, Montelukast, Albuterol/Salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Jun 26, 2026, 10:13 AM EDT
Recruiting Phase 3 Interventional

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NCT05799378
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jun 26, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

NCT04546399
View directory record Official record
Conditions
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
Radiation · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 150 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 26, 2026, 10:13 AM EDT
Withdrawn Phase 2 Interventional

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

NCT04223661
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide Pill, Dexamethasone, Daratumumab
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

NCT00066599
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jun 26, 2026, 10:13 AM EDT
Completed No phase listed Observational

Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults

NCT00179335
View directory record Official record
Conditions
HIV Infections
Interventions
Blood drawing to determine drug levels
Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 26, 2026, 10:13 AM EDT
Withdrawn Phase 2 Interventional

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01055301
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
21
States / cities
Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jun 26, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

NCT06799195
View directory record Official record
Conditions
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Interventions
Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus, Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CAPABLE Family Pilot - Adapting CAPABLE for Older Adults With Mild Cognitive Impairment (MCI)/Early Stage Dementia and Their Care Partners

NCT05187117
View directory record Official record
Conditions
Dementia, Mild, Mild Cognitive Impairment, Disability Physical, Impairment, Cognitive, Caregiver Burden, Quality of Life, Depression
Interventions
CAPABLE Family - Open Label Pilot, CAPABLE Family - Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Jun 26, 2026, 10:13 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315
View directory record Official record
Conditions
Wheezing, Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 5 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly

NCT01331161
View directory record Official record
Conditions
Shingles
Interventions
ZOSTAVAX
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years to 79 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Jun 26, 2026, 10:13 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

NCT03352765
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine, melphalan, Autologous Stem Cell Transplantation (ASCT)
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Immune Response to Heplisav in Healthy Older Adults

NCT01999699
View directory record Official record
Conditions
Hepatitis B
Interventions
HEPLISAV
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
50 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jun 26, 2026, 10:13 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Vaccination Responses in Young and Older Adults

NCT02654704
View directory record Official record
Conditions
Individuality, Healthy, Asthma, Immune System and Related Disorders
Interventions
Pneumococcal Vaccination
Biological
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jun 26, 2026, 10:13 AM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01880567
View directory record Official record
Conditions
CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive, Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Rituximab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 26, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

NCT03650400
View directory record Official record
Conditions
Asthma
Interventions
Fevipiprant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Minneapolis, Minnesota • Columbia, Missouri • Tulsa, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

NCT01716754
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Fresno, California • Hawaiian Gardens, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 2Phase 3 Interventional

Effectiveness of a Telephone-Delivered Behavioral Treatment to Improve the Quality of Life of Older Adults With HIV

NCT00365690
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Telephone-administered coping improvement therapy, Telephone-administered supportive-expressive therapy, Individual therapy
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

NCT01453023
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate, Fluticasone Furoate/Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Huntington Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jun 26, 2026, 10:13 AM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccine Feasibility Study in Children With Persistent Asthma

NCT02967393
View directory record Official record
Conditions
Asthmatic
Interventions
ccIIV4, IIV4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Jun 26, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional

Allo CART-19 Protocol

NCT01551043
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
CART-19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jun 26, 2026, 10:13 AM EDT